Taxane-based adjuvant therapy for early breast cancer (EBC): A meta-analysis of the predictive effect of ER and HER2 status (original) (raw)

Journal of Clinical Oncology, 2010

Abstract

e11025 Background: Taxane-based adjuvant chemotherapy regimens for EBC yield on average an improvement of disease-free-survival (DFS) and overall survival (OS) as compared to anthracycline-based regimens (De Laurentiis et al., JCO 2008). It has been questioned, however, that this average benefit may results from a markedly improved outcome for some subsets of patients, with others not receiving any advantage. To check this hypothesis, we performed a meta-analysis of the predictive effects both of HER2 and of ER status by pooling subsets data of the available randomized trials (RTs). The efficacy of taxane-based regimens in the subgroup of triple-negative (TN) pts was also evaluated. Methods: We searched the Pubmed database to identify randomized trials that compared taxane-based with non-taxane-based adjuvant chemotherapy regimens for EBC and reported efficacy data according to: HER2 or ER or the combination HER2/ER or the TN status. We also searched the proceedings of major international conferences to i...

Brigida Stanzione hasn't uploaded this paper.

Let Brigida know you want this paper to be uploaded.

Ask for this paper to be uploaded.